This Causes Lung Cancer To Be The Most Deadly Disease In The World, In Indonesia There Are 34,783 New Cases

Covesia.com – Based on data from GLOBOCAN 2020, lung cancer is the cause of about 11 percent or 2,206,771 new cases of cancer and number one cancer deaths in the world. Meanwhile, in Indonesia the cause of 8.8 percent or 34,783 new cases.

Lung cancer becomes dangerous and causes a risk of death, according to the General Chairperson of the Indonesian Cancer Foundation, Prof. Aru Sudoyo, Sp.PD-KHOM, because patients seek treatment when their condition is severe.

“As many as 80 percent of lung cancer patients come at an advanced stage, so the percentage of survival is lower. Therefore, it is very important to increase public knowledge about risk factors, symptoms and special considerations for lung cancer treatment,” said Prof. Aru, in a webinar held MSD Indonesia, quoted from Suara.com, Covesia.com network, Saturday (26/11/2021).

He explained, more than 80 percent of lung cancers that attack the community are non-small cell lung cancer (NSCLC) and about 40 percent of NSCLC have epidermal growth receptor (EGFR) mutations.

Once found, the average 5-year survival rate for lung cancer or the percentage of patients living at least five years is 21 percent. The 5-year average survival rate for men was 17 percent, while for women it was 24 percent. The 5-year survival rate for NSCLC is 25 percent, compared with 7 percent for small cell lung cancer.

Dr. Ralph Girson Ginarsa, SpPD-KHOM, internal medicine specialist and consultant medical oncology hematologist, explained that there are several subtypes of NSCLC, namely adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

Adenocarcinoma begins in cells that normally secrete a mucus-like substance and are usually found in people who smoke or have been smokers. In addition, it is also found in people who do not smoke, is generally found in women, and tends to be in people who are younger than other types of lung cancer. This type is found on the outside of the lungs and is likely to be found before it spreads.

The next subtype is squamous cell carcinoma which starts from the squamous cells which are flat cells in the lung airways. Patients with this subtype are closely associated with smoking habits, and tend to be found in the center of the lung near the bronchial tubes.

The large cell subtype of carcinoma, on the other hand, can be found anywhere in the lung and tends to grow and develop rapidly, making it more difficult to treat. There is a subtype of large cell carcinoma known as large cell neuroendocrine carcinoma, which is a cancer that grows rapidly and is similar to small cell lung cancer.

Meanwhile, epidermal growth factor receptor (EGFR) is a protein in cells that helps their growth. A mutation in the EGFR gene will cause it to overgrow, causing cancer. If the EGFR is negative, it means that the tumor cells in lung cancer do not have EGFR mutations.

“Symptoms of NSCLC lung cancer and other types of lung cancer often do not appear at an early stage, because lung cancer often has symptoms similar to other common diseases such as tuberculosis or as a result of long-term smoking habits. However, you need to be careful if someone feels tired, lethargic , with unexplained weight loss, worsening cough, bloody phlegm, hoarseness, shortness of breath, with repeated lung infections accompanied by fever, chest pain, and loss of appetite,” explained dr. Ralph.

On the same occasion, George Stylianou, Managing Director of MSD in Indonesia, said collaboration of the health industry with organizations such as the Indonesian Cancer Foundation is necessary. Therefore, the challenge of lung cancer cannot be faced by only one stakeholder.

There needs to be collaboration between industry, professional organizations, government, patient organizations, health professionals, and academia to find solutions for access to innovative drugs and opportunities to continue to raise public awareness about lung cancer.

“At MSD, we work with urgency to put patients first and ensure our innovative cancer drugs are accessible to patients in need. We are each driven by a shared vision to give all cancer patients more—more ways to treat their cancer, more quality in their lives, more time,” George.

.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Trending